[Daptomycin therapy in patients with bacteremia].

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Context:

• Healthcare-associated and nosocomial bacteremias are primarily caused by Gram-positive microorganisms, notably Staphylococcus species.
• High rates of methicillin resistance in Staphylococcus aureus (MRSA) and coagulase-negative staphylococci necessitate alternative treatments to vancomycin.
• Vancomycin's toxicity and treatment failures in MRSA infections with elevated MICs drive the search for safer, effective antibiotics.

Purpose:

• To evaluate daptomycin as an alternative to vancomycin for Staphylococcus aureus bacteremia.
• To provide evidence-based recommendations for daptomycin use in specific patient populations and clinical scenarios.
• To highlight the role of daptomycin in managing MRSA infections and critically ill patients.

Summary:

• Daptomycin demonstrates non-inferiority to vancomycin in treating S. aureus bacteremia and endocarditis.
• Guidelines recommend daptomycin for MRSA bacteremia with vancomycin MIC > 1 mg/L and in patients with renal dysfunction.
• Daptomycin is advised as a first-line agent for critically ill patients with suspected Gram-positive bacteremia in high-MRSA prevalence settings or with renal impairment.

Impact:

• Daptomycin offers a crucial treatment option for challenging Gram-positive bacteremias, particularly MRSA.
• Improved patient outcomes are expected with appropriate empirical and targeted therapy selection.
• This evidence supports updated clinical guidelines for antibiotic use in severe infections.